Basis: FMP quote market capitalization / revenue from four consecutive issuer fiscal quarters. Source: stored company filings and market data; unavailable inputs remain N/A.
The P/S ratio is N/A as of 2026-10-06T13:41:31.392Z.
Calculation as of: 2026-10-06T13:41:31.392Z.
Quote observation: 2026-10-06T13:40:14.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 953d1456faf84e3d3f88a5480ffc5766df2e412b5fda6c1fb2fa7c75cf2e613b
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
PS RATIO
N/A
Market Cap
$341.86M
PS Ratio
N/A
TTM Avg
73.59
3Y Avg
73.59
5Y Avg
73.59
Market Cap
$310.39M
PS Ratio
N/A
TTM Avg
995.02
3Y Avg
3050.37
5Y Avg
3251.65
| NAME | MARKET CAP | PS RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Cabaletta Bio, Inc. (CABA) | $334.26M | N/A | N/A | N/A | N/A |
| C4 Therapeutics, Inc. (CCCC)vs › | $329.49M | 9.40 | 9.47 | 10.08 | 12.64 |
| Artiva Biotherapeutics, Inc. (ARTV)vs › | $341.86M | N/A | 73.59 | 73.59 | 73.59 |
| ClearPoint Neuro, Inc. (CLPT)vs › | $348.63M | 8.25 | 11.34 | 10.16 | 11.34 |
| Embecta Corp. (EMBC)vs › | $348.85M | 0.34 | 0.45 | 0.65 | 0.90 |
| CapsoVision, Inc. (CV)vs › | $318.27M | 22.91 | 23.06 | 21.57 | 21.57 |
| Agenus Inc. (AGEN)vs › | $352.29M | 2.65 | 1.38 | 1.35 | 2.67 |
| Benitec Biopharma Inc. (BNTC)vs › | $310.39M | N/A | 995.02 | 3050.37 | 3251.65 |
| Opus Genetics, Inc. (IRD)vs › | $359.16M | 36.44 | 117.36 | 59.63 | 59.63 |
| Fennec Pharmaceuticals Inc. (FENC)vs › | $360.92M | 6.09 | 6.19 | 8.23 | 116.26 |
Trailing-12-month revenue adds these four fiscal quarters. Amounts are in USD, rounded only to whole currency units.
| Fiscal period | Revenue | Source |
|---|---|---|
| Q3 FY2025Period ended 2025-09-30 | $0 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2025-11-10 |
| Q4 FY2025Period ended 2025-12-31 | $0 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2026-03-23 |
| Q1 FY2026Period ended 2026-03-31 | $0 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2026-05-14 |
| Q2 FY2026Period ended 2026-06-30 | $0 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2026-08-13 |
| TTM revenue | $0 |
The current P/S calculation cannot be reconciled from the stored quote and revenue inputs.
These references are supplied through FMP. Full filing context identifiers and dimensional metadata are unavailable in the normalized feed.
P/S Ratio
N/A
Market Cap / Trailing Twelve-Month Revenue
PS Ratio = Market Cap / Revenue (TTM)
The price-to-sales ratio compares market capitalization to trailing revenue. It is useful for valuing companies with little or no earnings.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
